Pfizer: FDA grants priority review to prostate cancer drug

(CercleFinance.com) - The US Food and Drug Administration has granted a priority review for Pfizer and Astellas' drug Xtandi for the treatment of non-metastatic castration-resistant prostate cancer, the companies said on Tuesday.


The drugmakers today announced that a supplemental new drug application has been accepted for filing by the FDA.

Xtandi is currently indicated for the treatment of patients with metastatic castration-resistant prostate cancer.

The FDA has assigned July 2018 as a target date.


Copyright (c) 2018 CercleFinance.com. All rights reserved.